With GlaxoSmithKline in the rearview mirror, Abbas Hussain is ready to lead a biotech of his own; Doug Treco scores first CEO job since Ra Pharma buyout
→ Abbas Hussain was once considered to be a top candidate to take Andrew Witty’s place as CEO of GlaxoSmithKline in 2016. When the job was ultimately given to Emma Walmsley — who has been in her own spots of bother recently — Hussain quit as GSK’s global president of pharmaceuticals and vaccines in January 2017. Four years later, Hussain gets behind the CEO wheel at Swiss-based Vifor Pharma, which has a PDUFA date of Aug. 23 with its Cara–partnered drug Korsuva for pruritis in hemodialysis patients. Hussain officially takes over for the departing Stefan Schulze a week before that date on Aug. 16. Schulze had been in charge at Vifor since March 2020 and is leaving for personal reasons.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
